NIH Recombinant DNA Advisory Committee
Executive Summary
Will meet June 9 and 10 at the National Institutes of Health in Building 31C, Conference Room 6 at 9 a.m. Items to be discussed include a clinical trial to assess safety, efficacy, and cost of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis, a Phase I trial testing genetically engineered interleukin-7 melanoma vaccine, and a Phase I study examining injection of glioblastoma patients with tumor cells genetically modified to secrete IL-2